PM
NVCR icon

Parametrica Management’s NovoCure NVCR Stock Holding History

Parametrica Management’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-2,489
Closed -$312K – 155
2021
Q1 		$312K Buy
+2,489
New +$394K 0.15% 104
2020
Q3 		– Sell
-3,913
Closed -$232K – 137
2020
Q2 		$232K Buy
+3,913
New +$257K 0.25% 97

Other funds holding NVCR

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Parametrica Management's NVCR Position: Q2 2021 in Review

Parametrica Management sold out of NovoCure (NVCR) in Q2 2021, closing a stake of 2,489 shares — an estimated $312K sold.

Parametrica Management first reported a position in NVCR in Q2 2020 and held it in 2 quarters. The position peaked at $312K in Q1 2021. 361 funds tracked by Wall St. Rank hold NVCR as of Q2 2021.

  • Parametrica Management reported no remaining NovoCure position as of Q2 2021 after selling out during the quarter.
  • Parametrica Management sold 2,489 NovoCure shares in Q2 2021, an estimated $312K.
  • Parametrica Management first reported a position in NovoCure in Q2 2020 and held it in 2 quarters.
  • Parametrica Management's NovoCure position peaked at $312K in Q1 2021.
  • 361 funds tracked by Wall St. Rank held NovoCure as of Q2 2021.

Based on Parametrica Management's 13F filing for Q2 2021, filed 13 Aug 2021.